


PHARMACEUTICAL 2020

CNBX Pharmaceuticals Inc. Rank 8 of 362









PHARMACEUTICAL 2020



RealRate

CNBX Pharmaceuticals Inc. Rank 8 of 362

The relative strengths and weaknesses of CNBX Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CNBX Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 359% points. The greatest weakness of CNBX Pharmaceuticals Inc. is the variable Other Assets, reducing the Economic Capital Ratio by 146% points.

The company's Economic Capital Ratio, given in the ranking table, is 340%, being 642% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	4,307
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	439
Liabilities, Non-Current	0
Other Assets	9,874
Other Compr. Net Income	2,810
Other Expenses	288
Other Liabilities	0
Other Net Income	4,437
Property and Equipment	1,002
Research and Development	1,544
Revenues	9.8
Selling, General and Administrative Expense	1,482

Output Variable	Value in 1000 USD
Assets	15,183
Liabilities	439
Expenses	3,313
Stockholders Equity	14,744
Net Income	1,133
Comprehensive Net Income	2,538
Economic Capital Ratio	340%

